OC
MDGL icon

Oppenheimer & Co’s Madrigal Pharmaceuticals MDGL Stock Holding History

Oppenheimer & Co’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$264K Hold
492
– – ﹤0.01% 1532
2026
Q1 		$258K Buy
492
+100
+26% +$47.8K ﹤0.01% 1456
2025
Q4 		$228K Buy
+392
New +$200K ﹤0.01% 1381
2024
Q3 		– Sell
-1,310
Closed -$367K – 1555
2024
Q2 		$367K Buy
1,310
+90
+7% +$21.4K 0.01% 1115
2024
Q1 		$326K Buy
+1,220
New +$287K 0.01% 1148

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Oppenheimer & Co's MDGL Position: Q2 2026 in Review

Oppenheimer & Co held its Madrigal Pharmaceuticals (MDGL) position steady in Q2 2026 at 492 shares worth $264K. The position accounts for ﹤0.01% of the portfolio, ranked #1532.

Oppenheimer & Co first reported a position in MDGL in Q1 2024 and has held it in 5 quarters since. The position peaked at $367K in Q2 2024. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Oppenheimer & Co held 492 shares of Madrigal Pharmaceuticals worth $264K as of Q2 2026.
  • Oppenheimer & Co left its Madrigal Pharmaceuticals share count unchanged in Q2 2026.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Oppenheimer & Co's portfolio in Q2 2026, its #1532 holding.
  • Oppenheimer & Co first reported a position in Madrigal Pharmaceuticals in Q1 2024 and has held it in 5 quarters since.
  • Oppenheimer & Co's Madrigal Pharmaceuticals position peaked at $367K in Q2 2024.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.